Characteristics and treatment results of patients of risk group R2 in studies NHL-BFM90 and NHL-BFM95
. | NHL-BFM90 patients . | NHL-BFM95 patients . |
|---|---|---|
| No. patients in risk group R2 | 167 | 233 |
| % of study population | 40 | 46 |
| No. patients receiving R2 therapy | 154 | 222 |
| Male, % | 75 | 75 |
| Female, % | 25 | 25 |
| Age, y, median (range) | 9.6 (1.9-17.9) | 9.6 (2.5-19.7) |
| Burkitt, % | 69 | 62 |
| DLBCL, % | 17 | 28 |
| PMLBL, % | 4 | 2 |
| Other, % | 10 | 7 |
| Stage, % | ||
| I | 14 | 16 |
| II | 44 | 40 |
| III | 42 | 45 |
| Mediastinal tumor, no. patients | 13 | 12 |
| LDH, U/L, median (range) | 238 (80-3583) | 229 (57-654) |
| Events, no. | ||
| Death unrelated to tumor | 3 | 1 |
| Tumor failure | 2 | 10 |
| Second malignancy | 3 | 2 |
| pEFS, 3 years, % | 97 ± 1 | 95 ± 2 |
. | NHL-BFM90 patients . | NHL-BFM95 patients . |
|---|---|---|
| No. patients in risk group R2 | 167 | 233 |
| % of study population | 40 | 46 |
| No. patients receiving R2 therapy | 154 | 222 |
| Male, % | 75 | 75 |
| Female, % | 25 | 25 |
| Age, y, median (range) | 9.6 (1.9-17.9) | 9.6 (2.5-19.7) |
| Burkitt, % | 69 | 62 |
| DLBCL, % | 17 | 28 |
| PMLBL, % | 4 | 2 |
| Other, % | 10 | 7 |
| Stage, % | ||
| I | 14 | 16 |
| II | 44 | 40 |
| III | 42 | 45 |
| Mediastinal tumor, no. patients | 13 | 12 |
| LDH, U/L, median (range) | 238 (80-3583) | 229 (57-654) |
| Events, no. | ||
| Death unrelated to tumor | 3 | 1 |
| Tumor failure | 2 | 10 |
| Second malignancy | 3 | 2 |
| pEFS, 3 years, % | 97 ± 1 | 95 ± 2 |
DLBCL indicates diffuse large B-cell lymphoma; and PMLBL, primary mediastinal (thymic) large B-cell lymphoma.